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ABSTRACT
Blebbistatin,para-nitroblebbistatin (NBleb), andpara-aminoblebbistatin
(AmBleb) are highly useful tool compounds as they selectively
inhibit the ATPase activity of myosin-2 family proteins. Despite
the medical importance of the myosin-2 family as drug targets,
chemical optimization has not yet provided a promising lead for
drug development because previous structure-activity-relation-
ship studies were limited to a single myosin-2 isoform. Here we
evaluated the potential of blebbistatin scaffold for drug de-
velopment and found that D-ring substitutions can fine-tune
isoform specificity, absorption-distribution-metabolism-excretion,
and toxicological properties. We defined the inhibitory properties
of NBleb and AmBleb on seven different myosin-2 isoforms,
which revealed an unexpected potential for isoform specific
inhibition. We also found that NBleb metabolizes six times
slower than blebbistatin and AmBleb in rats, whereas AmBleb
metabolizes two times slower than blebbistatin and NBleb in
human, and that AmBleb accumulates in muscle tissues.
Moreover, mutagenicity was also greatly reduced in case of
AmBleb. These results demonstrate that small substitutions
have beneficial functional and pharmacological consequences,
which highlight the potential of the blebbistatin scaffold for drug
development targeting myosin-2 family proteins and delineate
a route for defining the chemical properties of further derivatives
to be developed.
SIGNIFICANCE STATEMENT
Small substitutions on the blebbistatin scaffold have beneficial
functional and pharmacological consequences, highlighting
their potential in drug development targeting myosin-2 family
proteins.
Introduction
Myosin-2 family proteins are the final effectors of cellular
and intracellular contractile processes and tension generation
ranging from cell division (Ma et al., 2012) to cell motility
(Vicente-Manzanares et al., 2009) and neuronal plasticity
(Kubo et al., 2008; Seabrooke and Stewart, 2011; Briggs et al.,
2017) to skeletal, cardiac, and smooth muscle contraction
(Szent-Gyorgyi, 1951, 1952; Johnson et al., 1994; Geeves and
Holmes, 1999; Sellers, 2000; Eddinger and Meer, 2007;
Brozovich et al., 2016; Tang et al., 2017). Therefore, myosin-
2 isoforms are promising drug targets in treatment of various
myosin- and cytoskeleton-related diseases, such as cancer,
neuropathies, and myopathies (Straight et al., 2003; Newell-
Litwa et al., 2015; Rauscher et al., 2018; Roman et al., 2018).
This study has been supported by the Hungarian National Research,
Development and Innovation Office [NVKP 16-1-2016-0051 to M.G., and A.M.-C.]
and the Hungarian Ministry of Finance [GINOP-2.1.7-15-2016-02580 to M.G.].
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As a myosin-2–specific inhibitor (Straight et al., 2003;
Limouze et al., 2004), blebbistatin (Straight et al., 2003)
can serve as a starting point for the development of clinical
drug candidate (Rauscher et al., 2018; Roman et al., 2018).
It has already been an excellent tool compound since its
discovery in unveiling the role of the myosin-2 family in
various biologic processes. Although the chemical optimi-
zation of blebbistatin was apparently fruitful in creat-
ing more photostable, less fluorescent, noncytotoxic, and
more water-soluble tool compounds for research (Rauscher
et al., 2018; Roman et al., 2018) through numerous chemical
optimization efforts (Lucas-Lopez et al., 2005, 2008; Lawson
et al., 2011; Képiró et al., 2012, 2014; Várkuti et al., 2016;
Verhasselt et al., 2017a,b,c; Roman et al., 2018), no lead
compound suitable for drug development have yet been
published.
However, structure-activity-relationship studies of blebbis-
tatin derivatives (Lucas-Lopez et al., 2005; Rauscher et al.,
2018; Roman et al., 2018) suggest that a substantial chemical
space available on the D-ring of compounds can be exploited
to fine-tune the biologic and physicochemical properties of
compounds. The structure-activity-relationship studies are in
line with the crystal structure where A-B-C tricyclic core of
blebbistatin fits tightly into the binding pocket and the D-ring
protrudes out of the binding pocket (Allingham et al., 2005),
providing substantial space for chemical alterations on this
part of the molecule.
Moreover, blebbistatin and our recently developed deriva-
tives azidoblebbistatin (Képiró et al., 2012), para-nitroblebbistatin
(NBleb) (Képiró et al., 2014), and para-aminoblebbistatin
(AmBleb) (Várkuti et al., 2016) have been applied as myosin-2
inhibitors in a series of in vivo diseasemodels (blebbistatin: Zhang
et al., 2009, 2011a,b; Gavin et al., 2011; Young et al., 2014, 2016,
2017; Briggs et al., 2017, 2018; Chen et al., 2018a,b; ABleb: Zenker
et al., 2018; NBleb: Letelier et al., 2018; AmBleb: van Opbergen
et al., 2018; Pénzes et al., 2020).
After our publications on the original synthesis, phys-
icochemical properties, and toxicity assessment of NBleb
and AmBleb (Képiró et al., 2014; Várkuti et al., 2016),
NBleb has recently also been used in a drug develop-
ment study focusing on the applicability of myosin-2 inhib-
itors in substance use relapse (patent WO2019/241469A1).
In this patent NBleb was identified as a useful compound
“for practice of an embodiment of the methods of the
invention.”
Moreover, we have recently shown that AmBleb can be
successfully used in ischemic stroke interventions due to its
direct relaxing effect on precapillary smooth muscle cells
(Pénzes et al., 2020), which otherwise remain permanently
closed after stroke, thereby hindering the restart of healthy
blood circulation at the capillary level even after recanaliza-
tion of large vessels (Hall et al., 2014; Hill et al., 2015). Despite
these promising effects in living systems, very little informa-
tion is available about the pharmacological properties of
blebbistatin, NBleb, and AmBleb.
The above observations motivated us to perform in-depth
characterization of these tool compounds, blebbistatin, NBleb,
and AmBleb, including their pharmacokinetic and pharmaco-
dynamic properties, in vivo distribution, genotoxicity, and
myosin-2 isoform specificity, which are essential to judge the




High-pressure liquid chromatography (HPLC)–grade acetonitrile,
chloroform and water were purchased from VWR (PA). Other
chemicals were purchased from Sigma-Aldrich (Germany) if not
otherwise stated. Blebbistatin was purchased from Sellekchem
(TX), and isoflurane was purchased from Rotacher-Medical
GmbH (Germany). Williams Medium E for freshly isolated
hepatocytes was purchased from ThermoFischer (MA). Ames
Microplate Format Mutagenicity Assay kit was purchased from
Xenometrix.
Inhibitory Properties of Blebbistatin, NBleb, and AmBleb on
Seven Myosin-2 Isoforms
Expression of Nonmuscle Myosin-2 Isoforms (Dictyostelium
Myosin-2, NM2A, NM2B, and NM2C). A single-tryptophanmutant
Dictyostelium motor domain construct (W501+) (Málnási-Csizmadia
et al., 2000) was expressed in Dictyostelium AX2-ORF+ cells and
purified with His-Tag affinity chromatography as described pre-
viously (Gyimesi et al., 2008). The Sf9 codon optimized sequences for
nonmuscle myosin-2 isoform (NM2) motor domains [M1-R775 for
NM2A, M1-R782 for NM2B (B0), and M1-R799 for NM2C (C0)] fused
to an Ala-Ser linker and an artificial a-actinin lever arm [as described
earlier for NM2C (Heissler and Manstein, 2011)] with C-terminal
FLAG-tag sequences were synthesized and cloned into pFastBac1
expression vector by Biomatik Co. The pFastBac1/NM2 constructs
were overexpressed in Sf9 cells after bacmid preparation form
DH10Bac cells. Sf9 cells were infected with P3 virus stocks, and
myosin constructs were expressed for 48 hours, 27°C, 135 rpm. To
reduce proteolytic digestion during expression, Pepstatin-A (0.1 mg/l)
was added to Sf9 cells (Gotoh et al., 2001).
Purification of Actin and Sarcomeric Myosin-2 Isoforms
(Skeletal, Cardiac, and Smooth Muscle Myosin-2s). Rabbit
actinwas prepared according to an earlier published protocol (Spudich
and Watt, 1971). Skeletal muscle myosin-2 was isolated from
rabbit fast muscles (m. psoas, m. latissimus dorsi, m. biceps
femoris) according to an earlier published protocol (Margossian and
Lowey, 1982), and subfragment-1 (SkS1) was prepared by applying
a-chymotryptic digestion (0.05 mg/ml a-chymotrypsin, 10 minutes,
25°C; reactionwas stoppedwith 3mMPMSF). Cardiacmusclemyosin
(CM) was isolated from left ventricle of porcine heart after cardiac
myofibril preparation protocol (Tong et al., 2008)with themodification
that 20 mM ATP (in Krebs-Hensleit buffer) was added to the final
washedmyofibril pellet, and the clear,myosin-containing supernatant
was dialyzed against Storage buffer (20 mM Tris pH 7.5, 200 mM
NaCl, 5mMMgCl2, 2mMb-mercaptoethanol) before freezing in liquid
nitrogen. Smooth muscle myosin was prepared from freshly slaugh-
tered chicken gizzard according to an earlier protocol (Trybus, 2000),
and subfragment-1 (SmS1) was prepared by activated papain di-
gestion according to a previously published protocol (Seidel, 1980)
(0.2 mg/ml papain, 12 minutes, 25°C; reaction was stopped with 5 mM
sodium iodoacetate).
ATPase Activity Measurements. Steady-state ATPase meas-
urements were carried out in 50 ml volume in a flat-bottom 384-well
plate (Nunc-Thermo Fischer) using an NADH-PK/LDH coupled assay
described earlier (Gyimesi et al., 2008) at 25°C in the presence of
0.5 mM ATP and F-actin (25 mM for W501+, NM2s; 11.5 mM for CM;
20 mM for SkS1; and 33 mM for SmS1) in a low ionic strength buffer
(10 mM MOPS pH 7.0, 4 mM MgCl2, 2 mM b-mercaptoethanol) for
15 minutes. Blebbistatin derivatives were added to the reaction in
0.5 ml DMSO (1% of total volume), and three parallels were measured
for each point. Controls containing DMSOwith myosin but no inhibitor
and actin-control containing actin and DMSO but no myosin were
measured in all measurement sets. Applied myosin concentrations
(100 nM SkS1, 200 nM W501+, 500 nM CM and SmS1, 1 mM NM2s)
were used to fit quadratic function. ATPase activity was calculated











from the slope of the linear fit to the time-dependent absorbance data
collected at 340 nm.
Inhibition of Muscle Force and In Vitro Motility by
Blebbistatin, NBleb, and AmBleb
Force Measurements on Muscle Fibers. Synaptically evoked
isometric force in the semi-intact larval bodywall preparation (Paterson
et al., 2010) of Drosophila was measured as described previously
(Ormerod et al., 2013). Briefly, Canton S strain Drosophila early
wandering stage third instar larvae were dissected in Hemolymph-
like (HL3.1) saline (10 mM NaHCO3, 115 mM sucrose, 5 mM
trehalose, 70 mM NaCl, 5 mM KCl, 4 mM MgCl2, 5 mM HEPES,
1.5 mM CaCl2  2H2O, #0.1% DMSO). Synaptic potentials were
elicited by stimulating a group of several segmental motoneurons via
a glass suction electrode, Grass S88 stimulator, and stimulus isolation
unit (Grass Technologies, West Warwick, RI). Single impulses were
generated at 0.2 Hz, 0.3ms pulse duration, and ∼125% of the voltage
needed to attain maximal compound excitatory junction potential
amplitude. A custom designed force transducer (Micron Instruments,
Simi Valley, CA) was used in all experiments to record evoked
contractions. Treatment with blebbistatin, NBleb, and AmBleb followed
the following routine: 1) baseline force generating ability was determined
after 10–15 minutes in HL3.1 saline; 2) response to blebbistatin,
NBleb, and AmBleb was determined during treatment (1–1000 mM
inhibitor in HL3.1 saline, #0.1% DMSO) for 10–20 minutes; and
3) reversibility of inhibition and baseline force generating ability was
evaluated after 10–15-minute washout in HL3.1 saline.
In Vitro Motility. Fluorescent actin filaments were made by
combining 1 mM tetramethyl-rhodamine with 1 mM actin in in vitro
motility assay buffer (25 mM imidazole, pH 7.4, 25 mM KCl, 4 mM
MgCl2, 1 mM EGTA, 1 mMDTT) containing 1 mM ATP. Movement of
polymerized F-actin filaments over full-lengthmyosin-coated surfaces
was achieved using amodification to themethod of Uyeda et al. (1990).
Movies were collected on an ImageXpress XL high content imaging
system at 25°C with a frame rate of 3 Hz and a 40 air objective.
Compound dose responses were collected at a final concentration of
2% DMSO, 40 mM 2 serial dilution. Custom analysis software was
created by VigeneTech, in which images were thresholded based on
pixel intensity, filaments were identified, trajectories were deter-
mined for each filament, and filament velocities for each movie were
calculated. Only filaments .2 mm and velocity of .25 nm/s were
analyzed. Three to four movies, each with 500–2000 filament
trajectories, from different surfaces were analyzed, and the
median velocities of these were averaged for a single n. Each
data point shown is a combination of three to four individual
experiments (n = 3 to 4, each containing 4000–20,000 filament
tracks per data point).
Molecular Dynamics Simulations
Molecular Dynamics Simulations for Blebbistatin Deriva-
tives. Molecular dynamics simulations and evaluations were carried
out using AMBER16. For the derivatives, partial charges were
calculated with the AM1-BCC charge model using the antechamber
program. Force field parameters for GAFF force field were appended
using parmchk2 based on atomic type similarity. Molecules were
explicitly solvated with three-site model (TIP3P) waters and energy-
minimized in 2000 steps of steepest descent followed by 4000 steps of
conjugate gradient minimization. After minimization, a 10-nanosecond
NPT simulation was carried out for eachmolecule at 1 bar pressure and
300 K temperature using Langevin dynamics for temperature coupling
with 5 picosecond21 collision frequencies. Sampleswere collected for the
charge distribution calculation every 10 picosecond.
Calculation of Time-Averaged Charge Distributions. The
structures of the trajectory were RMS-fitted to three atoms of
the tricyclic ring: the N atoms in the tricyclic ring and C6 atom of
the A-ring. Since these atoms are part of a conjugate system, they
remain fixed relative to one another during the simulations. We
defined a 1-Å resolution rectangular with the tricyclic rings plane as
the x, z plane of the ordinate system and the N linking the C and D
rings as its origin. We then derived the time-averaged charge
distribution by integrating the average density of each atom multi-
plied by its respective partial charge.
Simulations of the Myosin-Blebbistatin Complexes. The
ff14SB force field was used in all subsequent simulations to model
protein interactions. The initial structure of the Dictyostelium dis-
coideum myosin-2 head – blebbistatin complex was based on crystal
structure 3mjx.pdb. ADP.VO4 was replaced with ADP.PO4. The water
molecules resolved by crystallography were retained, and the model
was expanded in an 8-Å clearance dodecahedron box with three-site
model (TIP3P)watermolecules for explicit solvation. The complex was
minimized and heated in three 100-K 20-picosecond steps to 300 K
under NVT conditions, then subsequently equilibrated to 1 bar in
20 picoseconds under NPT conditions. The system was relaxed for
500 picoseconds under NVT conditions at 300 K, then further
equilibrated for 60 nanoseconds under NPT conditions, by which
time the structure’s root-mean-square deviation (RMSD) compared
with the initial structure had converged. Blebbistatin was replaced
with the nitro- and amino derivatives at this point to obtain the initial
structure for their relaxation. All three variants were re-equilibrated
using the same equilibration protocol as described above up to the
500-picosecond 300-K NVT step. The complexes were then further
equilibrated for 6 nanoseconds under NPT conditions to obtain the
final structures. The trajectories were sampled every 10 picoseconds
during the last 1 nanosecond of the simulation. The time-averaged
charge distribution within the protein was calculated using the
coordinates of blebbistatin atoms in these 100 frames with themethod
described for water solvent–only simulations. Side chain binding
enthalpy contributionswere calculatingwith themolecularmechanics
energies combined with the generalized Born and surface area
continuum solvation (MM-GBSA) method using the mmpbsa pro-
grams of AMBER.
In Vitro Metabolic Stability of Blebbistatin, NBleb, and
AmBleb
Pharmacokinetic Studies. After 2 days of accommodation the
rodents were randomly divided into three groups. Compounds were
administered intraperitoneally to each group 2.5, 5, 10, 15, 25, and
45minutes before tissue sampling. Control animals were treated with
0.9% NaCl solution. Blood samples were collected from the heart
under isoflurane inhalation anesthesia into test tubes containing
200 ml (500 IU/ml) heparin. Tissue samples from brain, heart, liver,
kidney, spleen, muscle, and urine were collected from different
animals after a 2-minute perfusion with Krebbs-Henseleit solution
via the aorta. Tissue samples were stored in 1ml chloroform at280°C.
Sample Preparation for HPLC–Mass Spectrometry Analy-
sis. Tissue samples mixed with chloroform were minced, vortexed,
and sonicated for 30 minutes. Samples were centrifuged (60,000g,
20 minutes, 4°C). The organic phase was collected and dried under
a fume-hood. To the dried tissue samples, appropriate amount of
acetonitrile-water mixture (50:50, v/v%) was added to the dried
material; samples were sonicated for 30 minutes and ultracentrifuged
(84,000g, 45 minutes, 10°C). After ultracentrifugation, supernatant
was collected into already weighed eppendorfs, and net weight of the
samples prepared for HPLC–mass spectrometry (MS) was deter-
mined. Ten microliters of supernatant was injected for HPLC-MS
analysis.
HPLC-MS Conditions. Chromatographic separation of the com-
pounds and metabolites was carried out using an HP Agilent 1100
series HPLC system consisting of G1312A binary pump, G1365B
multiwavelength detector, G1322A Degasser, G1313A auto sampler,
and Waters SQMass Spectral Detector (Waters Corporation, Milford,
MA). Chromatographic separation was achieved on an analytical C18
Merck Purospher STAR RP-18 endcapped (250 mm  4.6 mm, 5 mm)











column maintained at room temperature. Isocratic separation was
carried out with acetonitrile:water (50:50 v/v%) as the mobile phase
with the flow rate of 0.5 ml/min. The injection volume was 10 ml. Mass
detection of samples were conducted utilizing an electrospray source
in positive ion mode. Blebbistatin, NBleb, and AmBleb and their
metabolites were quantified based on peak areas of their respective
m/z values by extracted ion chromatograms from the single quadru-
pole scan measurements. For blebbistatin, NBleb, and AmBleb,
reference materials were readily available, and their limit of quanti-
fication was at least 300 pg [30 ng/ml sample concentration (equal to
0.1 mM) with the 10 ml injection volume applied]. The MassLynx 4.1
software was used for instrument control, data acquisition, and
evaluation.
High-Resolution Mass Spectrometry. High-resolution mass
spectrometric measurements were run on a SciexTripleTOF 5600+
hybrid quadrupole time-of-flight mass spectrometer (Sciex, MS)
equipped with TurboV ion source. Samples were measured under
electrospray condition in positive ion detectionmode. The resolution of
the instrument was 35,000. Source conditions were curtain gas: 45
arbitrary unit (AU), spray voltage: 5500 V, nebulizer gas: 40 AU,
drying gas: 45 AU, source temperature: 450°C, collision energy in MS/
MS experiment: 35 eV, scan time: 1 second. A Perkin Elmer Series 200
micro HPLC systemwith binary pumps and an autosampler was used
for online HPLC-HRMS measurements. A Merck Purospher Star C18
(55  2 mm, 3 mm) was used for the separation. The mobile phases
were water containing 0.1 v/v% formic acid (eluent A) and acetonitrile
containing 0.1 v/v% formic acid (eluent B). The flow rate was 0.5ml/min
linear gradient was used starting with 20% B and increasing to 90%
B by 8 minutes. This was followed by a 1-minute washing period with
90% B and returning to the initial conditions for 5 minutes for
equilibrating the system. The HPLC-MS system was controlled by
Analyst TF (Sciex, MA) software. Data were processed by PeakView
and MasterView software (Sciex).
Isolation of Primary Hepatocytes. Primary hepatocytes were
isolated from male Wistar rats (Toxi-Coop Toxicological Research
Center, Budapest, Hungary) and human tissue donors (Department of
Transplantation and Surgery, Semmelweis University, Budapest,
Hungary) using the collagenase perfusion method of Bayliss and
Skett (1996). Briefly, the liver tissues were perfused through the
portal vein with Ca2+-free medium (Earle’s balanced salt solution)
containing EGTA (0.5 mM) and then with the same medium without
EGTA, finally with the perfusate containing collagenase (Type IV,
0.25 mg/ml) and Ca2+ at physiologic concentration (2 mM). The
perfusion was carried out at pH 7.4 and at 37°C. Softened liver
tissue was gently minced and suspended in ice-cold hepatocyte
dispersal buffer. Hepatocytes were filtered and isolated by low-
speed centrifugation (50g) and washed three times. The yield and
percent of cell viability according to the trypan blue exclusion test
were determined (Berry et al., 1997). For pharmacokinetic studies,
the hepatocytes were suspended at 2  106 cells/ml concentration
in culture medium (Ferrini et al., 1998). Incubations with rat
hepatocytes isolated from four animals were performed individu-
ally, whereas human hepatocytes pooled from three tissue donors
were applied.
In Vitro Pharmacokinetics of Blebbistatin, NBleb, and
AmBleb. Time courses of the unchanged pharmacons (blebbistatin,
NBleb, and AmBleb) in primary hepatocytes were obtained. Each
compound was incubated with cell suspension (2 106 cells/ml) at 37°
C in a humid atmosphere containing 5% CO2. The parent compounds
dissolved in DMSO were added directly to the cell culture medium at
the final concentration of 30mM.The final concentration of DMSOwas
0.1%. At various time points (at 0, 5, 10, 20, 30, 45, 60, 90, 120, 180,
240minutes), the incubation mixtures were sampled (aliquots: 0.25ml)
and terminated by the addition of 0.25 ml ice-cold dichloromethane
containing the internal standard, carbamazepine (0.13 mM). Bleb-
bistatin and its derivatives were also incubated in cell-free medium
and sampled at 0 and 240 minutes. The liquid-liquid extraction step
was repeated two times, and the organic phases were collected and
evaporated. The extract was dissolved in 100 ml of acetonitrile-water
(50:50, v/v) and was analyzed by liquid chromatography–tandemMS
for quantitation of the parent compound.
Estimation of Pharmacokinetic Parameters. The intrinsic
clearance (Clint) for hepatocytes [ml/(min2  106 cells)] was calcu-
lated from the decrease in the concentration of the parent compound
as follows (Obach, 1999):
Clint ¼ DAUC
where the dose (D) was the target 30 nmol (in 1 ml) and
AUC ¼ B
b
The concentration at 0 minute (B) was 30 mM (30 nmol/ml), and b was
determined by fitting exponentials to the measured drug candidate
disappearance. As in our case D was numerically equal to B, and Clint
was equal to b per hepatocyte concentration (2  106 cells/ml):
Clint ¼ b ¼ ln2t1=2
For scaling up the Clint value to obtain Clint per whole liver (g)/bw (kg), the
cell concentration in the liver (cell number in rat liver: 1.17  108cells/g
liver, in human liver: 1.39  108cells/g liver), the ratio of the average
liver weight and average body weight parameters (for rat: 40 g/kg, for
human: 23.7 g/kg) were used. The value for predicted hepatic clearance
(ClH) was calculated as follows (Houston, 1994; Sohlenius-Sternbeck,
2006):
ClH ¼ Clint  liver=bwp  fu  pHPFClint  liver=bwp  fu
þHPF
where the hepatic plasma flow rate (HPF) is
HPF ¼ QHp  plasmablood ratio
To calculate ClH, the hepatic flow rate (QH for rat: 55.2 ml/min per
kilogram; for human: 20.7 ml/min per kilogram), plasma/blood ratio
(for rat: 0.63; for human: 0.57) and the unbound fraction of the
compound (fu) values were used (Davies and Morris, 1993; Szakács




internal  standard in  cell2 free medium
compound
internal  standard in  hepatocyte  suspension
The fu values for blebbistatin, AmBleb, and NBleb were 0.805, 0.916,
and 1.0, respectively. The bioavailability (%) was determined by using
the equation
F ¼ ð12EÞp100
where E is the hepatic extraction ratio:
E ¼ ClH
QH
In Vivo Pharmacokinetics of Blebbistatin, NBleb, and
AmBleb
Animals. Male Wistar rats (220–250 g) were obtained from Toxi-
Coop (Hungary). Animals weremaintained under standard conditions
(air-conditioned animal house at 25–28°C, relative humidity of 50%,
and a 12:12 hour light/dark cycles). The animals were provided with
water and diet pellets ad libitum. All experiments were conducted in
compliance with the Guide for the Care and Use of Laboratory











Animals (US National Institutes of Health publication no. 85-23,
revised 1996) and conformed to Directive 2010/63/EU of the European
Parliament. The protocols were approved by the review board of the
Department of Animal Health and Food Control of the Ministry of
Agriculture and Rural Development, Hungary (XIII./1211/2012).
Animal Research: Reporting of In Vivo Experiments (ARRIVE) guide-
lines were adhered to during the study (NC3Rs Reporting Guidelines
Working Group, 2010).
Compound Stability Tests. Thirty micromolars (diluted from
1mMDMSO stock) compounds in 0.5 ml blood sample were incubated
for 0, 20, 40, and 60, 120, 240 minutes at room temperature in an
Eppendorf tube supplemented with 30 IU/ml heparin. At each time
point 50 ml chloroform was added to 50 ml sample aliquots. Samples
were vortexed, sonicated, and centrifuged (60,000g, 20 minutes), and
organic layer containing compound was collected. Organic layer of
the respective samples was dried under fume-hood, and then dried
samples were redissolved in acetonitrile-water mixture (50:50,
v/v). Samples were then sonicated and ultracentrifuged (84,000g,
45 minutes, 10°C), and supernatant was collected. Net weight
of the supernatant of each sample was determined. Stability of
compounds was determined based on their peak area in HPLC
chromatograms using HPLC-MS protocol described under phar-
macokinetic studies in the following text.
In Vivo Pharmacokinetics: Time-Dependent Distribution of
Blebbistatin, NBleb, and AmBleb in Rats. All applied animals
were littermates and weighed between 220 and 230 g upon arrival
to the test facility. After 1 week of acclimatization, rodents were
randomly divided into three groups of seven intraperitoneally re-
ceiving 1 mg of blebbistatin, NBleb, or AmBleb dissolved in 100 ml
DMSO (34 mM for blebbistatin, 30 mM for NBleb, and 33 mM for
AmBleb), which DMSO volume is in the safe range for single
intraperitoneal dose (Bartsch et al., 1976; Gad et al., 2006). Due to
homogenousweights upon arrival and identical housing conditions, all
animals were 2806 5 g at the day of experiments. Note that 3.6 mg/kg
is below the adverse cardiovascular and respiratory effect level
determined for AmBleb in a separate study (Gyimesi et al., 2020).
Control animals were treated with DMSO. Blood samples were
collected from the heart under isoflurane inhalation anesthesia into
test tubes containing 200 ml (500 IU/ml) heparin. Tissue samples from
brain, heart, liver, kidney, spleen, muscle, and urine were collected
from different animals after a 2-minute perfusion with Krebbs-
Henseleit solution via the aorta. Tissue samples were stored in 1 ml
chloroform at 280°C. We note that adverse effects were not observed
at the site of DMSO injection in any organs, and no signs of inhibitor
precipitation was observed in the intraperitoneum after necropsy.
Sample Processing for HPLC-MS. Tissue samples were minced,
vortexed, and sonicated in chloroform for 30 minutes. Samples were
centrifuged (3000g, 20 minutes, 4°C). The organic phase was collected
and dried under a laminar box. Two hundredmicroliters acetonitrile-water
mixture (50:50, v/v) was added to the dried material and ultra-
centrifuged (45,000g, 45 minutes, 10°C). Ten microliters supernatant
was injected for HPLC-MS analysis.
Mutagenicity Test of Blebbistatin, NBleb, and AmBleb
Ames Reverse Mutagenicity Test. Ames microplate format
(Xenometrix) reverse mutagenicity assay was performed according
to the manufacturer’s guide on TA98 and TA100 bacterial strains in
the absence and presence of phenobarbital/b-naphtoflavone-induced
rat liver S9 fraction.We used phenobarbital/b-naphtoflavone–induced
liver S9 fractions due to the higher structural similarity of these two
componds to blebbistatin than that of Aroclor 1254, another possibly
applicable substance. Solubility-dictated maximal applied concentra-
tions of the inhibitors were 100 mM for blebbistatin and NBleb
(29 and 34 mg/ml, respectively) and 400 mM (123 mg/ml) for AmBleb in
4% DMSO solutions. Note that slight precipitation occurred at the
100 mM NBleb–containing wells in the case of TA100 strain and the
400 mM AmBleb–containing wells in both TA98 and TA100 strains;
therefore, those data points were not included in the analysis.
Results
ATPase Inhibition of Different Myosin-2 Isoforms by
Blebbistatin Derivatives. Actin-activated ATPase activi-
ties of seven different myosin-2 isoforms in the presence of
different concentrations of blebbistatin, NBleb, and AmBleb
were measured (Fig. 1; Table 1), and their solubility under
assay conditions was confirmed (Supplemental Methods;
Supplemental Table 1). As expected based on earlier results
(Képiró et al., 2014; Várkuti et al., 2016), both derivatives
inhibitedmyosin-2 isoforms similarly to blebbistatin (Straight
et al., 2003; Limouze et al., 2004; Eddinger et al., 2007; Wang
et al., 2008b; Heissler andManstein, 2011; Zhang et al., 2017).
However, on skeletal musclemyosin-2, NBleb showed reduced
IC50 value compared with those of blebbistatin and AmBleb.
These results indicate that the electron-withdrawing group in
the para position of the D-ring positively influences the
inhibitory properties of the molecule. The electron-donating
amino group in AmBleb resulted in significantly lower
maximal ATPase inhibition with similar IC50 values for the
NM2A and NM2B isoforms (Fig. 1; Table 1), further confirm-
ing that electron distribution in blebbistatin’s D-ring is an
important determinant of the inhibitory mechanism. We also
analyzed the inhibitory efficiency, defined as the maximal
extent of inhibition divided by the inhibitory constant (kinh =
Imax/IC50) (Table 1), which corresponds to the initial slope of
Fig. 1. Inhibition of the actin-activated ATPase activity of sevenmyosin-2 isoforms.Wemeasured the inhibitory effect of blebbistatin (A), NBleb (B), and
AmBleb (C) on the F-actin–activated ATPase activities of seven myosin-2 isoforms, as indicated. Hyperbolic functions were fitted to the relative ATPase
activity data points to determine IC50 and maximal inhibition (Imax) values for each myosin-2 isoform (Table 1). IC50 values for skeletal muscle myosin-2
were lower than the applied protein concentration; thus, a quadratic function was used to fit ATPase data to determine the IC50 and Imax parameters.
Data points represent averages 6 S.D. (n = 3–12) on (A–C).











the fitted hyperbola. The ratio of the inhibitory efficiencies
on skeletal and cardiac muscle myosin-2s showed drastic
differences among the three inhibitors. The ratio is 56 for
NBleb, whereas it is only 9.7 and 5.8 for blebbistatin and
AmBleb, respectively. This finding suggests that skeletal
muscle myosin specificity may be achieved by substituting
theD-ring of blebbistatinwith electron-withdrawing groups in
the para position. Moreover, these results suggest that D-ring
substitutions in the para position provide opportunities to
fine tune inhibition and enhance isoform specificity among
myosin-2s.
AmBleb Inhibits Force Generation. We characterized
how AmBleb inhibits force generation in in vivo muscle prepa-
rations usingmotoneuronal stimulation of muscle fibers. Briefly,
neuromuscular preparations from Drosophila larval body-
wall muscle were tested for force generating ability during
incubation with AmBleb. As control, force generating ability
was tested prior to incubation and after washout (Fig. 2A)
and compound excitatory junction potentials were recorded
before (pre-), during, and after (post-) application (Fig. 2B).
AmBleb inhibited force generation, whereas it did not
exhibit statistically significant change in amplitude of the
synaptic voltages recorded at the neuromuscular junction
(pre- 29.7 6 1.8 mV and post- 30.1 6 0.8 mV; ANOVA P =
0.55). Blebbistatin and NBleb effects were not character-
ized due to possible solubility-related precipitation of these
inhibitors to the surface of fibers hindering appropriate
measurements. This effect was not observed with AmBleb
due to the sixfold higher solubility of Ambleb in HL-3.1
saline buffer than blebbistatin and NBleb (Supplemental
Table 1). Concentration dependence of relative isometric
force gives 9 6 2 mM IC50 for AmBleb (Fig. 2C).
Blebbistatin Derivatives Inhibit In Vitro Motility.
We next characterized the motion-generating capability of
myosin in an in vitro motility assay by measuring the
movement of individual rhodamine-phalloidin–labeled actin
filaments over a myosin-coated surface (Uyeda et al., 1990).
Actin filament velocity movies were automatically and objec-
tively analyzed by a custom commercial software created by
VigeneTech to measure two different velocity parameters.
Briefly, these parameters are MVEL and TOP5%; MVEL is
the mean velocity of all moving filaments and TOP5% is the
mean of the top 5% of the velocity distribution across different
actin filament lengths. The mean values from many actin
velocity measurements using bovine b-cardiac full-length
myosin at 25°C were as follows: MVEL: 350 6 50 nm/s;
TOP5%: 800 6 70 nm/s (n = 9 exp, three preps). We next
measured the motility of myosin in the presence of different
concentrations of blebbistatin, NBleb, and AmBleb up to the
solubility limit of the inhibitors (Fig. 2D; Supplemental
Table 1). Both derivatives inhibited the velocity of actin gliding
similarly to blebbistatin in a dose-dependent fashion. The IC50 of
inhibition for blebbistatin, NBleb, and AmBleb was measured to
be 0.7 6 0.1, 4 6 1, and 3 6 1 mM, respectively.
Charge Distribution of Blebbistatin Derivatives in the
Blebbistatin Binding Pocket Influences the Conformation
of Key Functional Residues in Myosin-2. Previously it was
shown that the blebbistatin binding pocket is large enough to
easily accommodate D-ring substitutions (Képiró et al., 2014;
Verhasselt et al., 2017a). Here we calculated how D-ring
substitutions with different electron profiles influence the





























































































































































































































































































































































































































































































































































































































time-averaged charge distribution around the three inhibitors
in an explicit water box and in simulated myosin-bound
structures. In water box, AmBleb showed a drastically different
charge density profile around the para position of the D-ring,
as compared with the other two inhibitors, whereas it was very
similar for blebbistatin and NBleb (Fig. 3B). However, time-
averaged charge densitiy of NBleb within the blebbistatin
binding pocket of Dictyostelium myosin-2 became more similar
to that of AmBleb (Fig. 3B). More importantly, the different
charge densities around the D-ring of the inhibitors resulted in
significant differences in the conformation of key functional
residues of myosin-2 (Fig. 3C).
The major difference was observed in the inhibitor binding
energy contribution of Lys587, which was practically negligible
in blebbistatin and AmBleb (DGbleb = 0.006 6 0.009 kcal/mol
and DGAmBleb = 0.03 6 0.03 kcal/mol, calculated from two
independent runs on each inhibitor), whereas it was signifi-
cant in NBleb (DGNBleb = 20.5 6 0.3 kcal/mol). This residue
plays important role in phosphate (Pi) release during the
chemomechanical cycle of the myosin ATPase by blocking the
Pi release route during the power-stroke of myosin (Gyimesi
et al., 2008; Cecchini et al., 2010).
The other significant difference appeared in the orientation
of Phe466, which has been described as a residue interacting
with the D-ring of blebbistatin (Allingham et al., 2005). In the
NBleb structure the phenyl ring of Phe466 develops more
contact with the inhibitor, whereas it folds outwards in the
blebbistatin and AmBleb structures (Fig. 3C). These differ-
ences may be of importance because Phe466 is in a key position
between the switch-2 loop and the relay helix of myosin,
structural elements that are responsible for the initiation of
the powerstroke during myosin’s ATPase cycle (Málnási-
Csizmadia and Kovács, 2010).
Metabolism of Blebbistatin, NBleb, and AmBleb in
Primary Hepatocytes. We characterized the pharmaco-
kinetic properties in primary rat and human hepatocytes
(Fig. 4, A–C) to determine the metabolic stability and to
identify the major metabolites (Fig. 4, D–I) for all three
tool compounds.
In case of rat hepatocytes, pharmacokinetics of blebbistatin
could be fitted with a single exponential function with half-life
(t1/2) of t1/2,bleb = 20.2 minutes (Table 2). Three detectable
metabolites appeared in the experimentswithm/z=295 [M+H]+
and m/z = 309 [M + H]+ (Fig. 4D). Importantly, we detected the
metabolite m/z = 309 [M + H]+ at two different retention times
(5.35 and 6.35 minutes), which suggests that two different
species with the same molecular mass were formed in these
experiments. All three detectable metabolites of blebbistatin
were formed quickly (t1/2 between 3 and 10 minutes) and
decomposed with similar rates than that of the original
blebbistatin. We only determined the relative concentra-
tions of these metabolites due to possible difference in
molar extinction coefficients between blebbistatin and the
metabolite.
Compared with blebbistatin, NBleb showed markedly slower
eliminationkineticsbyrathepatocyteswith t1/2,NBleb=114minutes
(Fig. 4B; Table 2), which clearly suggests that the D-ring
substitution affects not only the inhibitory functions but also
the pharmacokinetic properties of blebbistatin. Similarly to
blebbistatin, metabolites could be detected with m/z = 340
[M +H]+ andm/z = 350 [M +H]+ (Fig. 4E). In agreement with
slower elimination kinetics of NBleb compared with blebbis-
tatin, the half-lives of formation of these metabolites were
also significantly slower. Although only relative concen-
trations were determined for these metabolites, we could
suspect that the metabolite with m/z = 350 [M + H]+ may
be the major metabolite in case of rat hepatocytes, as
the rate of formation of this molecule was similar to the
elimination kinetics of NBleb (t1/2,NBleb = 114 minutes,
t1/2,mz350 = 70 minutes). In contrast to those of blebbista-
tin, neither metabolites of NBleb decomposed during the
240-minute experiment, which suggests that these metabo-
lites are not substrates for the enzymes transforming blebbis-
tatin metabolites.
Fig. 2. Blebbistatin, NBleb, and AmBleb inhibit
force generation and motility. (A) Isometric force
generation in larval Drosophila bodywall neu-
romuscular preparation is reversibly inhibited
by AmBleb (red). Pretreatment (gray) and post
treatment (black) traces are shown for compar-
ison. (B) The intracellular voltage recordings
remain unaffected by AmBleb treatment. (C)
Concentration dependence of the relative isometric
force in the presence of AmBleb (average6S.E.M.).
(D) Concentration dependence of the sliding veloc-
ity of actin filaments in motility assay with cardiac
myosin in the presence of blebbistatin (blue), NBleb
(green), and AmBleb (red) (mean 6 S.D.).











Interestingly, AmBleb decomposition by rat hepatocytes
showed a markedly higher rate than that of NBleb but very
similar kinetics to that of blebbistatin (t1/2,AmBleb = 19.0
minutes) (Fig. 4C; Table 2), confirming that D-ring substitu-
tion at least in the para-position has functional and pharma-
cological consequences bymodulatingpharmacokinetic properties
of blebbistatin derivatives. Three detectable metabolites
withm/z = 310 [M +H]+,m/z = 350 [M +H]+, andm/z = 352
[M + H]+ could be detected during AmBleb biotransforma-
tion (Fig. 4F). Moreover, similarly to that of NBleb, the
metabolite with m/z = 350 [M + H]+ could be the major
metabolite of AmBleb because the half-life of its formation
(t1/2,mz350 = 24 minutes) was almost identical to that of
AmBleb elimination.
To investigate differences between the metabolic properties
of the three inhibitors in the presence of rat and human
hepatocytes, we performed the same experiments with
primary human hepatocyte samples (Fig. 4, A–C). Similar
decomposition kinetics was observed for blebbistatin and
AmBleb as with the rat hepatocytes, although AmBleb elimi-
nation kinetics was slightly slower by the human hepatocytes
(Table 2). However, the more than sixfold slower elimination
of NBleb could not be detected in case of human hepatocytes;
rather, a very similar rate was observed to that of blebbis-
tatin. Moreover, characteristic differences between the two
species could be observed in the metabolite profiles of the
three inhibitors (Fig. 4, G–I).
Although the metabolite of blebbistatin with m/z = 295
[M + H]+ could be detected, the rate of formation was 10-fold
slower (t1/2,mz295,rat = 3 minutes, t1/2,mz295,human = 28 minutes)
and it did not disappear until 300 minutes. Moreover, only
one species of metabolite with m/z = 309 [M + H]+ could be
detected, which elimination was concomitant with the forma-
tion of a new metabolite (not detected with rat hepatocytes)
with m/z = 311 [M + H]+, which metabolite did not disappear
until 300 minutes either.
In contrast to the experiments with the rat hepatocytes,
only one metabolite was formed from NBleb with m/z = 340
[M + H]+ and from AmBleb with m/z = 310 [M + H]+.
Interestingly, the metabolite with m/z = 350 [M + H]+ could
not be detected in either NBleb or AmBleb, which indicates
that the same metabolite is formed from NBleb and AmBleb
Fig. 3. Time averaged charge distribution of blebbistatin, NBleb, and AmBleb in water and in myosin-2–bound forms. (A) Chemical structure
of blebbistatin with A-D rings indicated. NBleb and AmBleb harbor a nitro and an amino group in para position of the D-ring, respectively.
(B) Time-averaged charge distribution of blebbistatin, NBleb, and AmBleb in water (upper three structures) and docked and equilibrated in
Dictyostelium myosin-2 structure in the ADP.Pi-bound pre-powerstroke state (lower three structures; transparent myosin structure is shown as
cartoon with the relay helix colored in salmon). The three inhibitors are shown as green sticks and the time-averaged charge distributions are
shown as spheres colored red for negative and blue for positive average charge values in a voxel (arbitrary units). Dotted surfaces represent the
simulated charge envelope in both conditions. (C) Structure of the blebbistatin-binding pocket of Dictyostelium myosin-2 in the ADP.Pi-bound
pre-powerstroke state, relaxed using molecular dynamics. Interacting side chains are shown as transparent sticks. The two side chains with
significantly different binding energy contributions, Phe466 in the tip of the relay helix (salmon) and Lys587, are highlighted as solid orange
sticks.











with rat hepatocytes and further suggests the absence of that
reaction pathway in the human hepatocytes.
Pharmacokinetic analyses were performed on results from
both rat and human primary hepatocytes, and pharmacoki-
netic parameters have been calculated for all three inhibitors
(Table 2). As expected from the similar kinetics of blebbistatin
and AmBleb in rat samples, hepatic extraction ratio (EH) was
almost identical for these two inhibitors, whereas NBleb had
somewhat lower EH levels. Consequently, the bioavailability
of blebbistatin and AmBleb was around 60%, whereas that of
NBleb was more than 80%. In human hepatocytes, pharma-
cokinetic behavior of blebbistatin was similar to that in rat
hepatocytes (t1/2 values in rat and human hepatocytes were
similar), whereas substantial differences were observed in the
rates of elimination of NBleb between rat and human. On the
other hand, the lower hepatic clearance (ClH) of all three
compounds in human hepatocytes than in rat cells was
considered to be associated with lower hepatic flow rate in
human (QH for rat: 55.2 ml/min per kilogram; for human:
20.7 ml/min per kilogram). Regarding the bioavailability
(F), it should be noted that prediction from hepatic clear-
ance may result in an overestimation. Bioavailability is
related to the total clearance (the sum of all clearances in
the organs that participate in the elimination of drugs,
e.g., intestine and kidney); therefore, intestinal metabolism
can be expected to decrease the bioavailability of orally
administered drugs, and renal clearance can also modify
the bioavailability in case of extensive renal elimination.
Fig. 4. Biologic stability of blebbistatin, NBleb, and AmBleb in rat and human hepatocytes. Time-dependent changes in the concentration of
blebbistatin (A), NBleb (B), and AmBleb (C) in the presence of rat (open circles) and human (solid circles) hepatocytes. Data points were fitted with single
exponential functions (Table 2). Relative concentrations of the major metabolites detected in rat (D–F) or human (G–I) hepatocytes are shown. OH-bleb
(m/z = 309) is a mixture of two identified isomers (cf. Fig. 5; Supplemental Fig. 2), in case of rat hepatocytes, whereas only one isomer could be detected
with human hepatocytes. (D) Double exponential function was fit to blebmz295, which showed quick formation (t1/2 = 3.7 minutes) and elimination (t1/2 =
87 minutes) of this metabolite. Both metabolites with metabolites with m/z = 309 showed similar kinetics indicating that all major metabolites could be
fully eliminated by rat hepatocytes in 300 minutes. (E) Single exponential functions were fit to data points showing that NBlebmz350 formed more slowly
(t1/2 = 70 minutes) than NBleb
mz340 (t1/2 = 28 minutes). (F) Single exponential function fit to AmBleb
mz350 (t1/2 = 24 minutes) indicates that this
metabolite could not be completely eliminated by rat metabolic enzymes, and formation of AmBlebmz352 is much slower than the formation of the other
two metabolites. (G) Single exponential function fit to blebmz295 indicate that—contrary to rat hepatocytes—human enzymes could not eliminate this
metabolite in 300 minutes. Formation of blebmz309 followed similar kinetics as with rat hepatocytes, and the rate of formation of blebmz311 followed
inverse kinetics as that of blebmz309, indicating that blebmz311 is formed from blebmz309 and that blebmz311 could not be further metabolized by human
hepatocytes. (H and I) The major difference between rat and human hepatocytes was the absence of the metabolite with m/z = 350 from both NBleb and
AmBleb samples. Both NBlebmz340 and AmBlebmz310 formed with similar kinetics as with rat hepatocytes, but the elimination phase of AmBlebmz310 was
not present until 300 minutes. Data points represent averages 6 S.D. (n = 4–12).











Although the assessment of total clearance would be
optimal, much information can be obtained from hepatic
clearance as well. In conclusion, all three compounds should
still be considered as drugs with high extraction ratios,
where elimination is mainly determined rather by the
hepatic blood flow extraction ratio than by the activities of
the metabolizing enzymes. It also indicates that further
modifications of blebbistatin should be performed to have
more favorable pharmacokinetic properties and to achieve
higher bioavailability values.
TABLE 2
Pharmacokinetic parameters of blebbistatin, NBleb, and AmBleb from experiments using rat and human hepatocytes
Clint = (ln2/t1/2)  ((cell number/tissue weight)/(cell number/incubation volume))  (liver weight/body weight), where t1/2 is the time required
to achieve 50% of the initial concentration at t = 0 min. ClH = (Clint  fu  HPF)/(Clint  fu + HPF), where HPF = QH  plasma/blood ratio, where
QH = 55.2 ml/min per kilogram for rat, 20.7 ml/min per kilogram for human, plasma/blood ratio = 0.63 for rat, 0.57 for human. EH = ClH/QH.
F (bioavailability) = 100*(12EH).
Substance t1/2 (min) Clint (ml/min per kilogram) ClH (ml/min per kilogram) EH F (%)
Rat
Blebbistatin 20.17 80.41 22.62 0.41 59.02
NBleb 114.30 14.19 10.08 0.18 81.74
AmBleb 18.98 85.46 24.08 0.44 56.38
Human
Blebbistatin 26.13 43.72 8.84 0.43 57.31
NBleb 20.31 56.25 9.75 0.47 52.88
AmBleb 52.15 21.91 7.43 0.36 64.11
Fig. 5. Identification of major metabolites of blebbistatin, NBleb, and AmBleb. Major metabolites of blebbistatin (1), NBleb (2), and AmBleb (3). The
exact positions of the hydroxyl groups on blebbistatin, NBleb, and AmBleb could not be determined; only the rings (A, C or D) that contained hydroxyl
substituent were identified. The keto-group in the B-ring was reduced in blebbistatin (1a), NBleb (2a), and AmBleb (3b). Based on kinetic analysis in
Fig. 4, the hydroxylation of blebbistatin on the C-ring (1e) occurs before the reduction of the B-ring keto-group (1b). N-Ac-AmBleb (3a) could be formed
fromNBleb by transient formation of AmBleb and further acetylation of the amine-group as in the case of AmBleb (cf. Fig. 4).N-Ac-AmBleb (3a) could be
further reduced on the keto-group of the B-ring (3e), which metabolite might also be formed by acetylation of 3b. This latter scenario is supported by the
kinetics of elimination of 4-OH-AmBleb=AmBlebmz310 (3b) and the formation kinetics of 4-OH-N-AcAmBleb=AmBlebmz352 (3e) shown on Fig. 4F.











Identification of Major Metabolites. Pharmacokinetic
analysis of blebbistatin, NBleb, and AmBleb in freshly
isolated hepatocytes showed that all three compounds were
extensively metabolized forming several metabolites (Fig. 4).
To identify these metabolites, the rat hepatocyte-incubated
samples were analyzed by high-resolution MS and MS/MS
(Fig. 5).
The keto-group on the B-ring could be reduced to hydroxyl in
all three inhibitors resulting in two enantiomer forms with
different chromatographic retention properties. This reduced
metabolite of all three inhibitors could be detected with
HPLC-MS analysis above [4-OH-bleb, m/z = 295 [M + H]+
(molecule “1a” on Fig. 5); 4-OH-NBleb, m/z = 340 [M + H]+
(2a); 4-OH-AmBleb, m/z = 310 [M + H]+ (3b)]. These results
indicate that the metabolites detected from the hepatocytes
with the same m/z values are equivalent to these metabolites.
The reduced derivatives are further hydroxylated either on
the C-ring as in the case of blebbistatin (1b) and NBleb (2b), or
on the A-ring as in the case of AmBleb (3c). Moreover, the
C-ring hydroxylated reduced blebbistatin (1b) is further
hydroxylated on the A-ring too, thereby forming a reduced
dihydroxy-blebbistatin metabolite (1c). Dihydroxyl deriva-
tives could not be identified among the metabolites of NBleb
and AmBleb.
Direct hydroxylation of blebbistatin, NBleb and AmBleb
was also detected, but with characteristic differences in the
hydroxylation patterns (Fig. 5). Blebbistatin is hydroxylated
on the A-, C-, and D-rings (1d, 1e, 1f), from which two species
could be detected with HPLC-MS analysis above with m/z =
309 [M + H]+. Direct hydroxylation of the C- and D-rings of
NBleb and AmBleb did not occur (Fig. 5), indicating that nitro-
or amino-substitution on the D-ring not only hinders D-ring
hydroxylation but also has an effect on the electron distribu-
tion of the C-ring as well, thereby preventing it from hydrox-
ylation. However, the reducedNBleb derivative, that is, 4-OH-
NBleb (2a), is hydroxylated on the C-ring as well (2b), which
does not occur with the reduced AmBleb form. Instead,
reduced AmBleb is hydroxylated on the A-ring (3c) similarly
to direct hydroxylation of AmBleb.
We could also identify a metabolite of blebbistatin withm/z
= 311 [M + H]+, which is the C-OH-blebbistatin with reduced
keto-group on its B-ring (1b). From the formation end
elimination kinetics of these metabolites with human hepato-
cytes (cf. Fig. 4G) we can assume that hydroxylation occurs
first, which is further reduced on the B-ring.
The major metabolite formed from AmBleb in pharmacoki-
netic assays with m/z = 350 [M + H]+ was identified as
N-acetylated metabolite of AmBleb (N-Ac-AmBleb) (3a). Fur-
thermore, thismetabolite was also identified as themetabolite
produced from NBleb with m/z = 350 [M + H]+ (c.f. Fig. 4, E
and F). This suggests that NBleb underwent reduction,
forming AmBleb that was further acetylated. The formation
of AmBleb from NBleb could not be detected, indicating that
N-acetylation is a much faster reaction than the reduction of
the nitro-group to amine-group. This fact was confirmed in the
pharmacokinetic assays with AmBleb demonstrating the
extensive formation of N-Ac-AmBleb. We also identified the
metabolite withm/z = 352 [M + H]+ as theN-Ac-AmBleb with
reduced keto-group on its B-ring (3e). From the formation end
elimination kinetics of these metabolites with rat hepatocytes
(cf. Fig. 4F) we can assume that B-ring keto-group reduction
occurs first, which is further acetylated to the amine-group.
We note that neither acetylated forms could be detected in
human hepatocytes, indicating that this enzymatic route is
missing from the human samples.
Time-Dependent Distribution of Blebbistatin, NBleb,
and AmBleb in Rats. To follow the time-dependent distri-
bution of the three compounds and their metabolites in living
rats, we injected 1mg each of blebbistatin, NBleb, andAmBleb
intraperitoneally into 28065 g animals, resulting in 3.6mg/kg
dose level with 2% accuracy due to weight differences in rats.
Assuming an even distribution, the 1 mg inhibitor dose
applied should result in ∼15 mM per animal concentration.
At different time points after drug administration, samples
were collected from heart, blood, skeletal muscle (m. quadri-
ceps femoris), brain, kidney, lung, spleen, and liver tissues
(Fig. 6).
Inhibitor concentrations and metabolites were analyzed
by HPLC-MS. Stability of all three compounds in blood
(Supplemental Fig. 1) was similar, and the metabolism of all
three inhibitors was rapid. Their concentrations were well
below 5 mM at all time points in all tissue types except for
muscle. Interestingly, blebbistatin and AmBleb concentra-
tions increased over time in muscle samples, suggesting an
accumulation of these two inhibitors in skeletal muscle
tissue (Fig. 6). This phenomenon was not observed for heart
muscle tissue. The substantially lower tissue concentration
of NBleb compared with that of blebbistatin and AmBleb
may indicate insufficient NBleb solubility at the point of
administration. Even though NBleb solubility in general is
only slightly worse than that of blebbistatin (Supplemental
Fig. 1), NBleb can precipitate into needle-like crystals
(Várkuti et al., 2016), which may negatively affect its
effective concentration in vivo.
From the MS spectra the three OH-bleb metabolites (1d–1f)
could be identified with characteristically different retention
times (RT1 = 4.0 minutes, RT1 = 5.3 minutes, RT1 = 6.3
minutes) (Supplemental Fig. 2). The kinetics and tissue
distribution of the threemetabolites showed characteristically
different properties (Fig. 6). The OH-blebRT4.0 appeared in the
kidney in the highest concentration, whereas OH-blebRT6.3
was observed in the liver in the highest concentration. The
OH-blebRT5.3 metabolite was quickly formed but also quickly
eliminated from all tissues; however, a slight accumulation of
this metabolite was observed in the muscle tissue samples
similar to the original blebbistatin.
4-OH-NBleb (2a) metabolite of NBleb predominantly
appeared in the liver samples, remained high for 60 minutes,
and showed a tendency to increase in the kidney 10 and
60 minutes after NBleb injection (Fig. 6). In agreement with
the results from the hepatocyte experiments, AmBleb could
not be detected in tissue samples after NBleb injections;
however, the N-Ac-AmBleb metabolite (3a) was observed in
high concentration in the liver. The presence of N-Ac-AmBleb
in the liver samples and the lack of detectable amount ofN-Ac-
AmBleb in any other tissues suggest that AmBleb is quickly
formed in the liver and further acetylates in place.
However, N-Ac-AmBleb (3a) could be detected in all tissue
samples after AmBleb injection although with drastically
higher concentrations in the liver. Similarly to that observed
for N-Ac-AmBleb metabolite formed from NBleb, N-Ac-
AmBleb formed from AmBleb did not accumulate in any
tissue types, and its concentration was significantly higher
in the liver. In both cases, N-Ac-AmBleb is almost completely











eliminated at 60 minutes, suggesting quick elimination of this
metabolite from the body.
Reverse Mutagenicity (Ames) Test of Blebbistatin,
NBleb, and AmBleb. We tested the mutagenicity of all
three compounds in a reverse mutagenicity Ames test
using two Salmonella strains sensitive for frameshift
(TA98 strain) and base-pair substitution (TA100 strain)
mutations in the Ames microplate format mutagenicity
assay (Flückiger-Isler et al., 2004; Flückiger-Isler and
Kamber, 2012) in the absence and presence of liver S9
fraction (Fig. 7). A molecule is indicated Ames positive
(i.e., probably mutagenic) if it shows drug concentration-
dependent mutagenicity or any measured data point falls
above the mutagenicity threshold defined as twice of the
average plus S.D. of the solvent control (Fig. 7).
Importantly, whereas blebbistatin and NBleb were muta-
genic, AmBleb was not mutagenic in the absence of S9
fractions. Under these conditions, both for the TA98 and
TA100 strains, the slope of the linear fit to concentration-
dependent mutagenicity profiles of AmBleb was either nega-
tive or close to zero, respectively, indicating that the com-
pound does not reach the mutagenicity threshold (Fig. 7D).
However, in the presence of liver S9 fraction all three
compounds showed concentration-dependent mutagenicity,
and some data points fell above the mutagenicity threshold
for all three compounds (Fig. 7, B–D). The same metabolites
were produced during incubation with S9 liver fraction as in
the experiments with the isolated hepatocytes (cf. Fig. 4)
confirmed by high-resolution MS and MS/MS.
Among all investigated conditions, NBleb was the most
mutagenic in the presence of S9 liver fraction in the TA100
strain. Whereas the nitro-group increased mutagenicity,
especially base-pair substitution mutations, the amino group
substitution significantly decreased blebbistatin’s mutagenic-
ity, supporting our previous findings that the nitro-group has
an inverse effect on key biologic and pharmacological pro-
cesses (such as ATPase inhibition, cell permeability, and
pharmacokinetic profile) as compared with the amino sub-
stitution (cf. Figs. 1–6). This finding implies that substitution
of the D-ring of blebbistatin at the para position with electron-
donating groups can be used to significantly decrease its
mutagenic properties.
Discussion
Blebbistatin was discovered in a high-throughput assay
screening for cytokinetic furrow ingression arrest, targeting
nonmuscle myosin-2 functions (Straight et al., 2003). Blebbis-
tatin has been further shown to influence additional NM2-
related cellular functions (Melendez-Vasquez et al., 2004;
Ponsaerts et al., 2008; Wang et al., 2008a; Walker et al.,
2010). Moreover, NM2 isoforms—expressed in all human cell
types—generate forces during cell division (Ma et al., 2012),
regulate neuronal plasticity (Seabrooke and Stewart, 2011;
Fig. 6. Distribution of blebbistatin, NBleb, and AmBleb and their metabolites in different tissues of living rat. (Labeling in parentheses indicate the
nomenclature used in Fig. 5.) Time-dependent concentrations of blebbistatin, NBleb, and AmBleb were determined in different tissue types (as indicated
on the graphs) after intraperitoneal administration to living rats. Significant accumulation of blebbistatin and AmBleb could be observed in muscle
tissue samples, whereas NBleb did not appear in muscle samples in a detectable amount at any time points. After blebbistatin injection (blue bracket),
4-OH-bleb (1a) and the mixed populations of hydroxy-blebbistatin metabolites (1d–1f) were detected (Supplemental Fig. 2). After NBleb injection (green
bracket), 4-OH-NBleb (2a) could be detected in all tissue samples, whereas N-Ac-AmBleb (3a) was present only in the liver. Shaded arrows indicate the
assumed formation of AmBleb on the route of N-Ac-AmBleb formation, as suggested by MS/MS analysis. After AmBleb injection (red bracket), N-Ac-
AmBleb (3a) was detected in all tissue types except for muscle samples. 4-OH-N-Ac-AmBleb (3e) could also be detected in the tissue samples, and the
arrow indicates the possible route of its formation form 4-OH-AmBleb (3b) as suggested by the kinetics in Fig. 4F. Data points represent averages6 S.D.
(n = 4).











Briggs et al., 2017), and contribute to cellularmovements (e.g.,
in macrophages, fibroblasts, and cancer cell metastases)
(Vicente-Manzanares et al., 2009).
Beside its effects on NM2 isoforms, blebbistatin has been in
the focus of interest in developingmyosin-2–specific drugs due
to the involvement of myosin-2 motor proteins in several
essential life processes. Myosin-2 isoforms are responsible for
voluntary contraction of skeletal muscles (Szent-Gyorgyi,
1951; Geeves and Holmes, 1999) and that of the diaphragm
(Johnson et al., 1994); cardiac myosin-2s drive the pumping of
the heart (Szent-Gyorgyi, 1952; Tang et al., 2017), and smooth
musclemyosin-2 is a key component of tensionmaintenance in
blood vessels and the unconscious movements of our organs
(Eddinger and Meer, 2007; Brozovich et al., 2016). Thus,
blebbistatin is a highly potent nonselective myosin-2 inhibitor,
indicating a general mechanism of inhibition on all myosin-2
isoforms (Kovács et al., 2004; Limouze et al., 2004;Wilson et al.,
2014; Tang et al., 2017; Zhang et al., 2017). NBleb and AmBleb
have also been shown as potent inhibitors of Dictyostelium and
fast skeletal myosin-2s (Képiró et al., 2014; Várkuti et al., 2016;
Verhasselt et al., 2017a), but their inhibitory properties have
not been studied on other myosin-2 isoforms.
Thus, the development of drugs that could regulate myosin-
2 functions—especially in a selectivemanner—is an important
approach especially because myosins are the most downstream
effectors of signaling pathways, and thisway side effects related
to upstream regulators can be avoided. For drug development
purposes, isoform selectivity is an important feature; therefore,
we investigated whether inhibitory efficiency and myosin-2
isoform specificity profile can be tuned by D-ring substitutions
and how the D-ring substitutions affect the inhibition of in vivo
force generation or in vitro motility.
In the present study, we show that essential inhibitory and
absorption, distribution, metabolism, excretion, and toxicology
(ADMET) properties can be improved by chemical optimization.
Actin-activated ATPase measurements on seven myosin-2 iso-
forms, in vitro actin gliding measurements on cardiac myosin,
and in vivo fiber studies onDrosophila skeletalmuscle confirmed
that D-ring–modified blebbistatin derivatives retain their in-
hibitory potential on the myosin-2 family, whereas it is possible
to tune their selectivity toward the different myosin-2 isoforms.
For skeletal muscle myosin NBleb showed a reduced IC50 value
in the actin-activated ATPase assay and in vivo fiber studies
(Fig. 1; Table 1), for the cardiac system, both NBleb and AmBleb
have higher IC50 values as comparedwith blebbistain, as verified
both by actin-activated ATPase and in vitro actin gliding
measurements (Figs. 1 and 2A). Comparing the inhibitory
efficiency of the three inhibitors on skeletal and cardiac muscle
myosin-2s, we found that the ratio between skeletal and cardiac
myosin-2s is 6 times and 10 times higher forNBleb than those for
blebbistatin and AmBleb, respectively (Table 1). This feature
highlights a very important indication for further drug de-
velopment toward a skeletal muscle myosin-specific compound.
This aspect is especially important as skeletal muscle myosin
inhibition would be a novel approach for the treatment of
spasticity in poststroke conditions or in patients with multiple
sclerosis, cerebral palsy, or medication-induced spasms, where
currently there is a huge unmet medical need for more efficient
drugs without neurologic side effects (Chou et al., 2004; Chang
et al., 2013).
The pharmacodynamics and metabolic stability studies
indicate that although it is necessary to improve several
properties of blebbistatin for drug development purposes,
D-ring modifications can be very promising in terms of
absorption-distribution-metabolism-excretion optimization.
An important pharmacological parameter that needs to be
improved is the ∼20-minute metabolic half-life of blebbistatin,
as this rapid elimination could result in insufficient plasma
concentration, hindering the medical application of the com-
pound. Although rapid elimination of AmBleb similar to that
Fig. 7. Reverse mutagenicity (Ames) test of
blebbistatin, NBleb, and AmBleb in the absence
and presence of induced rat liver S9 fraction. (A)
Ames microplate format test plate triplicates
with TA98 Salmonella strain in the presence of
AmBleb (concentrations are indicated in micro-
molars). DMSO and 2-nitrofluorene were used as
negative and positive controls, respectively,
according to the manufacturer’s protocol. Dark
wells represent conditions with no bacterial
growth, whereas white wells contain growing
bacteria assuming a reverse mutation in their
genome. Relative mutagenicity of blebbistatin
(B), NBleb (C), and AmBleb (D) tested on TA98
(lighter circles) and TA100 (darker circles)
Salmonella strains in the absence (open circles)
and presence (solid circles) of rat liver S9
fraction. The dashed red line indicates the
mutagenicity threshold, defined as twice the
average plus S.D. of the solvent control. All three
inhibitors showed concentration-dependent in-
crease in mutagenicity, and all three compounds
produced values (individual data points) over
the mutagenicity threshold. *Linear fits excluded
measurements where precipitation was observed.
Importantly, AmBleb is not mutagenic in the
absence of rat liver S9 fraction; however, in the
presence of rat liver S9 fraction even AmBleb
shows concentration-dependent mutagenicity
in both strains. FDA, US Food and Drug Admin-
istration; OECD, Organization for Economic Co-
operation and Development.











os blebbistatin was demonstrated in rat hepatocytes, much
lower elimination half-life and Clint was found in human cells.
The rate of AmBleb metabolism would be close to sufficient
for human uses with multiple doses per day prescription.
In contrast, although NBleb was known to have increased
chemical stability (Verhasselt et al., 2017a), and in rat hepa-
tocytes, it showed increased biologic stability with elimination
kinetics fivefold slower than that of blebbistatin (Fig. 4;
Table 2), human liver cells were as active in metabolism of
NBleb as in that of blebbistatin. Moreover, given that a small
change such as amino-to-nitro substitution can have this
remarkable effect on elimination time, we may expect to be
able to find substituents with further improved pharmacoki-
netic properties. These findings, however, emphasized the
importance of species differences in drug metabolism and
careful extrapolation from laboratory animals to human.
Furthermore, parallel metabolic routes and variations in
the activities of drug metabolizing enzymes can also contrib-
ute to interindividual differences in pharmacological efficacy
or adverse effects. Similarly to NBleb metabolic pathways,
nitro-group reduction to an amino-derivative by CYP3A4 that
is further acetylated byN-acetyl transferase 2 (NAT2) are well
described steps in clonazepam metabolism (Peng et al., 1984).
However, hydroxylation pathway is considered to be negligi-
ble in case of clonazepam. Clonazepam plasma concentrations
seem to be influenced by CYP3A4 activity, whereas 7-amino-
clonazepam concentrations depend on the activities of both
CYP3A4 and NAT2 (Tóth et al., 2016). Interindividual
variations in the activities of CYP3A4 and NAT2 can results
in clinical consequences. The metabolite 7-amino-clonazepam
is pharmacologically inactive; however, it can competitively
modify the effect of clonazepam, primarily when the concen-
tration decreases after discontinuation of clonazepam ther-
apy. Therefore, clinical consequences are anticipated for the
patients with high levels of 7-amino-clonazepam during
clonazepamwithdrawal. In contrast, hydroxylation at various
positions was the major route of blebbistatin metabolism,
N-acetylation of the amino-group was the primary reaction
of AmBleb metabolism, and in NBleb metabolism, nitro-
reduction to amino-derivative (and further acetylation) and
hydroxylation at various positions were observed. Various
metabolic pathways and the activities of the phase I (mainly
cytochrome P450 enzymes) and phase II N-acetyl trans-
ferase enzymes are assumed to be associated with differ-
ent pharmacokinetic behavior of blebbistatin and two of its
derivatives.
One of the most important tests at early stages of drug
development is a mutagenicity assay. Due to the unambig-
uous correlation between mutagenicity and carcinogenicity
(McCann et al., 1975), Organization for Economic Cooperation
and Development, US Food and Drug Administration, and
European Medicines Agency guidelines all require the clear
demonstration that a lead compound is not mutagenic. The
minimal requirement is to test mutagenicity in a reverse
mutagenicity Ames test using two Salmonella strains sensi-
tive for frameshift (TA98 strain) and base-pair substitution
(TA100 strain) mutations. Guidelines also suggest repeating
the test in the presence of induced S9 rat liver fraction to
elucidate the mutagenicity of the potential metabolites pro-
duced in the liver during metabolism of the compound in the
living organism. Although we found that blebbistatin and
NBleb are clearly mutagenic, AmBleb is onlymutagenic in the
presence of S9 liver fraction, indicating that only AmBleb
metabolites are mutagenic and AmBleb itself is not muta-
genic. Although the genotoxicity of blebbistatin derivatives
must be prudentially improved, given that the small differ-
ence between the amino- and nitro-substituted derivatives
have drastic effect on mutagenicity, we may manage to
design and synthesize future compounds with fully eliminated
mutagenicity.
Conclusions
Blebbistatin derivatives are promising candidates for selec-
tive inhibition of myosin-2 isoforms. However, recently de-
veloped molecules do not meet the safety criteria to enter
preclinical studies due to their harmful properties of cytotox-
icity and genotoxicity described in this paper. Despite these
current limitations, our results provide useful and promis-
ing indications for further development of drug candidates
targeting myosin’s blebbistatin-binding site. Through dif-
ferent para substitutions on the D-ring, we could either
increase the inhibitory efficiency, improve skeletal muscle
selectivity, modify biologic stability, or drastically reduce
mutagenicity—properties that are necessary for the develop-
ment of a potentially useful lead compound to advance to
clinical trials for severe medical indications. Based on these
observations we believe that it is feasible to develop clinically
applicable drug compounds.
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